(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Contents:
Part I. General Topics
Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems
Richard M. Simon
Analytical Aspects of Biomarker Immunoassays in Cancer Research
Fred C. G. J. Sweep, Chris M. G. Thomas, and Manfred Schmitt
Tissue Microarrays: State of the Art, Pitfalls, and Promises
Chungyeul Kim and Soonmyung Paik
Part II. Assays for Gene Expression and Post-Translational Protein Abnormalities
Gene Expression Profiling with DNA Microarrays: Revolutionary Tools to Help Diagnosis, Prognosis, Treatment Guidance, and Drug Discovery
Michele De Bortoli and Nicoletta Biglia
Part III. Assays for DNA Abnormalities
Assays for Gene Amplification: State of the Art, Pitfalls, and Promises
Chungyeul Kim, Yongkuk Song, and Soonmyung Paik
Part IV. Tissue Predictive Biomarkers
Cell Kinetics
Maria Grazia Daidone, Rosella Silvestrini, and Dino Amadori
Urokinase-Type Plasminogen Activator and PAI-1: Validated Prognostic Factors for Breast Cancer
Michael J. Duffy
Predictive Value of c-erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer
Vered Stearns
erb-B2 as a Therapeutic Target
Robert Mass
The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer
Fortunato Ciardiello, Teresa Troiani, and Giampaolo Tortora
p53 as a Prognostic and Predictive Indicator
Daniela Kandioler and Raimund Jakesz
Part V. Predictive Biomarkers in Body Fluids
Occult Metastatic Cells in Breast Cancer Patients: State of the Art, Pitfalls, and Promises
Stephan Braun, Julia Seeber, and Christian Marth
Circulating HER2/neu: Clinical Utility
Allan Lipton, Laurence Demers, Kim Leitzel, Suhail M. Ali, Rainer Neumann, Christopher P. Price, and Walter P. Carney
Circulating Vascular Endothelial Growth Factor: Methods, Prognostic Significance, and Potential Application for Antiangiogenic Therapy
Roberta Sarmiento, Roberta Franceschini, Sabrina Meo, Massimo Gion, Raffele Longo, and Giampietro Gasparini
Detection of Early Tumor Dissemination in Patients with Breast Cancer
Debra Hawes and Richard J. Cote
Part VI. Future Directions
New Technologies/New Markers/New Challenges
Daniel F. Hayes and Giampietro Gasparini
Index
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: December, 2010
Pages: 354
Weight: 521g
Availability: Available
Subcategories: Oncology
From the same series
